Laparoscopic Ultrasound-Guided Removal of Multiple Uterine Fibroids
Laparoscopic Ultrasound-Guided Laparoscopic Myomectomy for Multiple Uterine Fibroids: A Prospective Randomized Controlled Trial
This study will examine whether ultrasound guidance during laparoscopic surgery can help surgeons remove uterine fibroids more completely. Uterine fibroids are noncancerous growths in the womb (uterus). Small fibroids or those deep in the uterine wall may be difficult to identify during surgery. Laparoscopic ultrasound uses a probe inside the abdomen to provide images of the uterus during the operation.
The study plans to enroll 110 premenopausal women aged 20 to 50 who have multiple uterine fibroids, need surgery, and wish to keep their uterus. Participants will be assigned by chance to laparoscopic ultrasound-guided myomectomy or conventional laparoscopic myomectomy, with 55 participants planned for each group. Myomectomy is surgery to remove fibroids while preserving the uterus.
The main outcome is the percentage of fibroids removed. For each participant, this is calculated by dividing the number of fibroids removed during surgery by the total number removed plus the number remaining on postoperative imaging, and multiplying by 100. Remaining fibroids will be assessed by transvaginal ultrasound or pelvic magnetic resonance imaging within 3 months after surgery.
Researchers will also assess the percentage of participants with remaining fibroids at 3 months, the difference between the number of fibroids removed and the number identified before surgery, surgical safety, postoperative recovery, and questionnaire scores related to sexual function, disability, anxiety, and quality of recovery. Follow-up visits are scheduled at 1, 3, and 12 months after surgery.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
Preoperative magnetic resonance imaging will be used to assess and count uterine fibroids. During laparoscopic ultrasound-guided myomectomy, the ultrasound probe will be placed in direct contact with the uterus to help locate fibroids and guide their removal. This approach is intended to improve identification of small or deep fibroids that may not be apparent on visual inspection. In both study groups, decisions about fibroid removal will be individualized, with clinical benefit and safety as the priorities.
Allocation will use stratified block randomization based on age, fibroid number, and maximum fibroid diameter, with a block size of four. A statistician who is not involved in recruitment or clinical intervention will generate the randomization sequence. Group assignments will be kept in sequentially numbered, sealed, opaque envelopes and revealed after completion of the baseline assessment and confirmation of enrollment.
Surgeons will be aware of treatment allocation. Outcome assessors and data analysts will remain blinded to group assignment.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Xiali Xiong
- Numer telefonu: +86-13520418824
- E-mail: xiongxiali2009@163.com
Lokalizacje studiów
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chiny, 100024
- Beijing Chao Yang Hospital, Capital Medical University
-
Kontakt:
- Xiali Xiong
- Numer telefonu: +86-13520418824
- E-mail: xiongxiali2009@163.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Symptomatic multiple uterine fibroids causing symptoms such as abnormal uterine bleeding, anemia, or pressure symptoms, with an indication for laparoscopic myomectomy and a desire to preserve the uterus.
- Diagnosis established through clinical evaluation, preoperative transvaginal ultrasound, and magnetic resonance imaging (MRI), with MRI used for the final assessment and fibroid count.
- Age 20 to 50 years and premenopausal, with or without future fertility plans.
- No contraindications to laparoscopic surgery.
Exclusion Criteria:
- Concomitant submucosal fibroids classified as FIGO types 0-2.
- Findings suspicious for malignancy on preoperative assessment.
- Uterine size equivalent to 20 weeks of gestation or greater; a history of pelvic inflammatory disease; severe endometriosis; grade III or IV uterine prolapse; or a history of intestinal obstruction, recurrent pelvic inflammatory disease, pelvic tuberculosis, or surgery for pelvic or abdominal tumors.
- Known severe hepatic or renal dysfunction.
- Known hematological disorders, bleeding or coagulation disorders, active bleeding at any site, or a bleeding tendency.
- Severe central nervous system, cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrine or metabolic, musculoskeletal, or psychiatric disorders. Endocrine or metabolic disorders include thyroid disease, Cushing's syndrome, and hyperprolactinemia.
- Acute infection.
- Inability to sign the informed consent form.
- Known or suspected poor adherence that would prevent completion of the study.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Pojedynczy
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Laparoscopic Ultrasound-Guided Myomectomy
Participants will undergo laparoscopic myomectomy with intraoperative laparoscopic ultrasound guidance to locate uterine fibroids and assist their removal. |
During laparoscopic myomectomy, a laparoscopic ultrasound probe will be placed in direct contact with the uterus to identify and localize fibroids and guide their removal. Fibroid removal will be individualized according to clinical benefit and safety. |
|
Aktywny komparator: Conventional Laparoscopic Myomectomy
Participants will undergo conventional laparoscopic myomectomy without intraoperative laparoscopic ultrasound guidance. |
Uterine fibroids will be removed using conventional laparoscopic myomectomy without intraoperative laparoscopic ultrasound guidance. Fibroid removal will be individualized according to clinical benefit and safety. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Fibroid Removal Rate
Ramy czasowe: During surgery and within 3 months after surgery
|
For each participant, the fibroid removal rate is calculated as the number of fibroids removed during surgery divided by the sum of the number removed during surgery and the number of residual fibroids detected by postoperative transvaginal ultrasonography or pelvic magnetic resonance imaging, multiplied by 100. |
During surgery and within 3 months after surgery
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Operative Time
Ramy czasowe: During surgery
|
Duration of the surgical procedure, measured in minutes. |
During surgery
|
|
Residual Uterine Fibroid Rate
Ramy czasowe: 3 months after surgery (+/- 14 days)
|
Percentage of participants with at least one residual uterine fibroid detected by transvaginal ultrasonography or pelvic magnetic resonance imaging at the 3-month postoperative visit. The rate is calculated as the number of participants with residual fibroids divided by the total number who underwent surgery in each group, multiplied by 100. |
3 months after surgery (+/- 14 days)
|
|
Difference Between Removed and Preoperatively Identified Fibroid Counts
Ramy czasowe: Preoperative assessment and during surgery
|
For each participant, the difference is calculated as the number of fibroids removed during surgery minus the number identified on preoperative magnetic resonance imaging. |
Preoperative assessment and during surgery
|
|
Estimated Intraoperative Blood Loss
Ramy czasowe: During surgery
|
Estimated volume of blood lost during surgery, measured in milliliters. |
During surgery
|
|
Participants With Intraoperative Complications
Ramy czasowe: During surgery
|
Number of participants experiencing at least one intraoperative complication, including hematoma, ureteral injury, or neurovascular injury. |
During surgery
|
|
Participants With Postoperative Complications
Ramy czasowe: From completion of surgery through 12 months after surgery (final visit window: +/- 14 days)
|
Number of participants experiencing at least one postoperative complication, assessed during postoperative hospitalization and at scheduled follow-up visits. |
From completion of surgery through 12 months after surgery (final visit window: +/- 14 days)
|
|
Postoperative Length of Hospital Stay
Ramy czasowe: Perioperative
|
Time from completion of surgery to hospital discharge, measured in days. |
Perioperative
|
|
Postoperative Pain Score
Ramy czasowe: 2 and 6 hours after surgery
|
Postoperative pain intensity assessed using a visual analog scale at 2 and 6 hours after surgery. Higher scores indicate more severe pain. |
2 and 6 hours after surgery
|
|
Time to First Postoperative Ambulation
Ramy czasowe: Perioperative
|
Time from completion of surgery to first postoperative ambulation, measured in hours. |
Perioperative
|
|
Time to First Postoperative Flatus
Ramy czasowe: Perioperative
|
Time from completion of surgery to first passage of flatus, measured in hours. |
Perioperative
|
|
Duration of Postoperative Uterotonic Treatment
Ramy czasowe: Perioperative
|
Duration of postoperative uterotonic medication use, measured in hours. |
Perioperative
|
|
Time to Postoperative Drain Removal
Ramy czasowe: Perioperative
|
Time from completion of surgery to removal of the surgical drain, measured in hours, among participants with a drain placed. |
Perioperative
|
|
Participants With Postoperative Urinary Dysfunction
Ramy czasowe: 1, 3, and 12 months after surgery (each visit window: +/- 14 days)
|
Number of participants with postoperative urinary dysfunction, assessed at each scheduled follow-up visit. |
1, 3, and 12 months after surgery (each visit window: +/- 14 days)
|
|
Participants With Postoperative Bowel Dysfunction
Ramy czasowe: 1, 3, and 12 months after surgery (each visit window: +/- 14 days)
|
Number of participants with postoperative bowel dysfunction, assessed at each scheduled follow-up visit. |
1, 3, and 12 months after surgery (each visit window: +/- 14 days)
|
|
Change From Baseline in Female Sexual Function Index Score
Ramy czasowe: Baseline (before surgery), 3 months, and 12 months after surgery (postoperative visit windows: +/- 14 days)
|
Change from the preoperative baseline in the total Female Sexual Function Index score at each postoperative assessment. The questionnaire assesses sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. Higher scores indicate better sexual function. |
Baseline (before surgery), 3 months, and 12 months after surgery (postoperative visit windows: +/- 14 days)
|
|
Change From Baseline in Oswestry Disability Index Score
Ramy czasowe: Baseline (before surgery), 1, 3, and 12 months after surgery (postoperative visit windows: +/- 14 days)
|
Change from the preoperative baseline in the Oswestry Disability Index score at each postoperative assessment. The questionnaire assesses disability associated with lower back or leg pain. Higher scores indicate greater disability. |
Baseline (before surgery), 1, 3, and 12 months after surgery (postoperative visit windows: +/- 14 days)
|
|
Change From Baseline in Zung Self-Rating Anxiety Scale Score
Ramy czasowe: Baseline (before surgery), within 48 hours after surgery, and 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
|
Change from the preoperative baseline in the Zung Self-Rating Anxiety Scale score at each postoperative assessment. The questionnaire contains 20 items assessing anxiety symptoms. Higher scores indicate more severe anxiety. |
Baseline (before surgery), within 48 hours after surgery, and 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
|
|
15-Item Quality of Recovery Questionnaire Score
Ramy czasowe: Within 48 hours after surgery and at 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
|
Total score on the 2025 Chinese version of the 15-item Quality of Recovery questionnaire at each postoperative assessment. Total scores range from 0 to 150, with higher scores indicating better quality of recovery. Changes between postoperative assessments will be evaluated. |
Within 48 hours after surgery and at 1, 3, and 12 months after surgery (monthly visit windows: +/- 14 days)
|
Współpracownicy i badacze
Sponsor
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 2026-sci-844-1
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
There is no plan to share de-identified individual participant data with researchers outside the study team.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .